Clinical Trials

182 enrolled

Multiple Myeloma

NCT05583617 2026-04-03

PLYCOM

200 enrolled

Multiple Myeloma

NCT07116616 2026-04-03

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

166 enrolled

Multiple Myeloma, Recurrence

NCT07510100 2026-04-03

FUMANBA-04

17 enrolled

Multiple Myeloma, Recurrence

NCT03761108 2026-04-01

LINKER-MM1

387 enrolled 3 FDA

Multiple Myeloma, Recurrence

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT05828511 2026-03-19

LINKER-MM4

149 enrolled

Multiple Myeloma

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT07454187 2026-03-06

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT06235229 2026-02-25

DURGA-3

110 enrolled

Multiple Myeloma

NCT07336472 2026-02-25

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

360 enrolled

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT07421856 2026-02-19

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

24 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

200 enrolled

Multiple Myeloma, Recurrence

NCT05535244 2026-02-09

CAMMA 2

90 enrolled

Multiple Myeloma

NCT03933735 2026-02-06

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

220 enrolled

Multiple Myeloma

NCT06988488 2026-02-02

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT05590377 2026-01-30

iinnovate-3

15 enrolled 12 charts

Multiple Myeloma

NCT03215030 2026-01-29

iinnovate-1

272 enrolled 67 charts

Multiple Myeloma

NCT06106945 2026-01-27

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

226 enrolled

Multiple Myeloma

NCT05714839 2026-01-23

DREAMM-20

153 enrolled

Multiple Myeloma, Recurrence

NCT04586426 2026-01-16

RedirecTT-1

228 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT04824794 2025-12-22

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

130 enrolled

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02328014 2025-12-09

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

40 enrolled 12 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06049290 2025-12-04

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

342 enrolled

Multiple Myeloma

NCT03837509 2025-11-04

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

15 enrolled 15 charts

Multiple Myeloma, Recurrence

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04582539 2025-10-22

LIMBER

Classical hematologyMyeloidPlasma cell

22 enrolled 28 charts

Anemia, Multiple Myeloma, Myelodysplastic Syndromes

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies